Please use this identifier to cite or link to this item:
Title: Novel hormonal agents for metastatic Castration-Resistant Prostate Cancer: comparing outcomes. A single-center retrospective study
Authors: Jarimba, Roberto Saldanha
Eliseu, Miguel Nobre 
Pedroso Lima, João
Quaresma, Vasco
Moreira, Pedro
Nunes, Pedro Coelho 
Silva, Edgar Tavares da 
Figueiredo, Arnaldo José 
Keywords: Prostate cancer; Abiraterone; Enzalutamide; Castration-resistant
Issue Date: 20-Dec-2021
Serial title, monograph or event: Archivio Italiano di Urologia e Andrologia
Volume: 93
Issue: 4
Abstract: Prostate cancer is the most common cancer in men, accounting for 15% of all diagnosed cancers and is the sixth leading cause of cancerrelated deaths amongst men worldwide. Abiraterone and enzalutamide were the first two novel hormonal agents approved for the treatment of metastatic prostate cancer but there is a lack of quality evidence regarding which is associated with better outcomes and who would benefit the most with one or another of these drugs.
ISSN: 2282-4197
DOI: 10.4081/aiua.2021.4.393
Rights: openAccess
Appears in Collections:FMUC Medicina - Artigos em Revistas Internacionais

Show full item record

Google ScholarTM




Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.